Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 38, 2023 - Issue 1
Submit an article Journal homepage
1,489
Views
1
CrossRef citations to date
0
Altmetric
Review Article

Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease

Dajiang Zoua College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, ChinaView further author information
,
Renzheng Liua College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, ChinaView further author information
,
Yangjing Lva College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, ChinaView further author information
,
Jianan Guoa College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, ChinaView further author information
,
Changjun Zhanga College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7088-146XView further author information
ORCID Icon &
Yuanyuan Xiea College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China;b Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceutical, Zhejiang University of Technology, Hangzhou, China;c Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education, Key Laboratory of Pharmaceutical Engineering of Zhejiang Province, Hangzhou, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8482-9948View further author information
ORCID Icon
Article: 2270781 | Received 07 Aug 2023, Accepted 27 Sep 2023, Published online: 13 Nov 2023

Figures & data

Figure 1. AChEIs approved by the FDA for AD therapy.

Figure 1. AChEIs approved by the FDA for AD therapy.

Figure 2. Three rational design strategies to generate multifunctional molecules.

Figure 2. Three rational design strategies to generate multifunctional molecules.

Figure 3. Structures of promising MTDLs.

Figure 3. Structures of promising MTDLs.

Figure 4. Structures of natural and synthesised chalcone.

Figure 4. Structures of natural and synthesised chalcone.

Figure 5. Structures of compound 1-based derivatives.

Figure 5. Structures of compound 1-based derivatives.

Figure 6. Structures of chalcone and donepezil-based dual inhibitors.

Figure 6. Structures of chalcone and donepezil-based dual inhibitors.

Figure 7. Structures of other chalcone-based dual inhibitors.

Figure 7. Structures of other chalcone-based dual inhibitors.

Figure 8. SAR of chalcone-based dual inhibitors targeting AChE and MAO-B.

Figure 8. SAR of chalcone-based dual inhibitors targeting AChE and MAO-B.

Figure 9. Structures of coumarin-based inhibitors.

Figure 9. Structures of coumarin-based inhibitors.

Figure 10. SAR of coumarin-based dual inhibitors targeting AChE and MAO-B.

Figure 10. SAR of coumarin-based dual inhibitors targeting AChE and MAO-B.

Figure 11. Structures of chromone-based inhibitors.

Figure 11. Structures of chromone-based inhibitors.

Figure 12. SAR of chromone-based dual inhibitors targeting AChE and MAO-B.

Figure 12. SAR of chromone-based dual inhibitors targeting AChE and MAO-B.

Figure 13. Structures of benzo five-membered ring-based inhibitors.

Figure 13. Structures of benzo five-membered ring-based inhibitors.

Figure 14. Structures of imine and hydrazone-based inhibitors.

Figure 14. Structures of imine and hydrazone-based inhibitors.

Figure 15. Structures of other scaffold-based inhibitors.

Figure 15. Structures of other scaffold-based inhibitors.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.